Mirum Pharmaceuticals Inc (MIRM)

Jan 13, 2025, 8:30 AM EST - 4 days ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Jan 10, 2025, 6:30 PM EST - 7 days ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 8, 2025, 11:05 AM EST - 9 days ago

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)

Jan 6, 2025, 4:04 PM EST - 11 days ago

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 25, 2024, 10:00 AM EST - 23 days ago

Mirum Pharma: Buy At Dips For Volixibat Potential

Nov 14, 2024, 8:00 AM EST - 2 months ago

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting

Nov 12, 2024, 1:51 PM EST - 2 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:00 AM EST - 2 months ago

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:30 PM EST - 2 months ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 4, 2024, 4:30 PM EST - 2 months ago

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Oct 31, 2024, 8:30 AM EDT - 2 months ago

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Oct 10, 2024, 8:30 AM EDT - 3 months ago

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

Aug 9, 2024, 9:10 PM EDT - 5 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 5 months ago

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 4:30 PM EDT - 6 months ago

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Jul 25, 2024, 8:30 AM EDT - 6 months ago

Mirum's LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Jul 17, 2024, 3:48 AM EDT - 6 months ago

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Jul 8, 2024, 8:30 AM EDT - 6 months ago

Mirum Pharmaceuticals' LIVMARLI Approved in the European Union for Patients with PFIC

Jun 28, 2024, 8:30 AM EDT - 7 months ago

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Jun 27, 2024, 4:48 PM EDT - 7 months ago

3 Biotech Stocks For The Second Half Of 2024

ALT NTLA

Jun 17, 2024, 10:53 AM EDT - 7 months ago

Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies

Jun 17, 2024, 8:00 AM EDT - 7 months ago

Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

Jun 16, 2024, 5:00 PM EDT - 7 months ago

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

Jun 5, 2024, 4:05 PM EDT - 8 months ago

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 31, 2024, 8:30 AM EDT - 8 months ago

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

May 29, 2024, 8:30 AM EDT - 8 months ago

Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

May 18, 2024, 7:00 AM EDT - 8 months ago

Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting

May 11, 2024, 2:25 PM EDT - 8 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:02 PM EDT - 9 months ago

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:10 PM EDT - 9 months ago

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

May 7, 2024, 8:30 AM EDT - 9 months ago

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

FSV

May 1, 2024, 4:10 PM EDT - 9 months ago

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Apr 22, 2024, 3:04 PM EDT - 9 months ago

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 2, 2024, 8:30 AM EDT - 10 months ago

Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

Mar 13, 2024, 6:49 PM EDT - 11 months ago

US FDA approves expanded use of Mirum's liver disease drug

Mar 13, 2024, 6:00 PM EDT - 11 months ago

Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

Mar 5, 2024, 5:29 AM EST - 11 months ago

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Feb 28, 2024, 8:57 PM EST - 11 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:03 PM EST - 11 months ago

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Feb 21, 2024, 4:05 PM EST - 11 months ago

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024

Jan 16, 2024, 8:30 AM EST - 1 year ago

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

Jan 8, 2024, 8:30 AM EST - 1 year ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

Jan 3, 2024, 8:45 AM EST - 1 year ago

Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 19, 2023, 9:10 AM EST - 1 year ago

Mirum Pharmaceuticals: Market Overreacts To Livmarli's Phase 2 Miss

Dec 18, 2023, 8:30 AM EST - 1 year ago

Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia

Nov 20, 2023, 4:05 PM EST - 1 year ago

Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference

Nov 13, 2023, 2:00 PM EST - 1 year ago

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

Nov 5, 2023, 1:51 AM EDT - 1 year ago

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript

Nov 3, 2023, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update